Eledon Pharmaceuticals, Inc. ELDN
2.61 USD +0.15 (+5.89%)
At closeNov 6, 2026, 4:26 PM EST
2.61 0.00 0.00%
After hours · Nov 6, 4:26 PM ET
2.50 Day range 2.66
1.39 52-week range 4.21
- YTD
- +72.52%
- 1 year
- -36.46%
News
benzinga.com Eledon Pharma Reports Improved Quality Of Life And Reduced Symptom Burden With Tegoprubart In Kidney Transplant Patients At ASN Kidney Week 2026 Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom
benzinga.com Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus…
benzinga.com Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026 Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus…
benzinga.com Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of…
benzinga.com This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
benzinga.com This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
benzinga.com Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12 Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares…- benzinga.com NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L…
- benzinga.com Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and plans to initiate the trial in late 2026.Under the agreement, Natera’s Prospera test will serve as…
benzinga.com Eledon Pharma Announces New Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation, Presented At ATC 2026 Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61…- benzinga.com Eledon Pharmaceuticals Announces Updated Results From A Trial Evaluating Tegoprubart, Its Investigational Anti-CD40L Antibody; All 12 Patients Treated In The Study Showed Rapid Improvement In Glycemic Control Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of…
- benzinga.com Eledon Pharmaceuticals To Present Updated Data From Investigator-Initiated Study At American Diabetes Association 86th Scientific Sessions Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant…
benzinga.com EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into human trials.- benzinga.com Eledon Pharma To Highlight New Clinical Data From Tegoprubart Program In Patients Undergoing Kidney Transplantation In Oral And Poster Presentation At ATC 2026 Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an…
benzinga.com Eledon Pharma Q1 EPS $(0.33) Misses $(0.18) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 312.5 percent decrease over losses of…- benzinga.com Eledon Pharmaceuticals Files Prospectus For Offering $500M Securities https://www.sec.gov/Archives/edgar/data/1404281/000119312526201426/d79008ds3.htm
benzinga.com EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.- benzinga.com NewcelX Advances Diabetes Program With New Drug Partnership With Eledon Pharma To Prevent Transplant Rejection NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Dow Dips Over 200 Points; Fluor Shares Slide After Q3 Results - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 56 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 64 companies achieved new lows for the year.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 212 companies made new 52-week lows.
benzinga.com Earnings Scheduled For May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its…- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 220 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday's session saw 337 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 479 stocks made new 52-week lows.
- benzinga.com Earnings Scheduled For November 14, 2022 Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
- benzinga.com Earnings Scheduled For August 11, 2022 Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
- benzinga.com Earnings Scheduled For May 12, 2022 Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 242 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 524 stocks hit new 52-week lows.
- benzinga.com Earnings Scheduled For November 11, 2021 Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.
- benzinga.com Earnings Scheduled For August 12, 2021 Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
- benzinga.com Earnings Scheduled For May 13, 2021 Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.